Craif’s Scientific Advisor & Co-Founder Yasui Introduces “Urinary MicroRNA-based Early Cancer Detection Using Nanowire-based Devices” in EUON
Craif Announces Extended Series B Funding
Craif Announces Office Move to Accommodate Accelerated Growth
Craif launches “miSignal™” series which enables early-stage cancer detection using urinary miRNA. The first test from the series will be for ovarian cancer available from 1st Feburary.
Craif Chubu Test Center is registered as a Clinical Laboratory
Craif and Tokio Marine & Nichido Life Insurance Announce a new Partnership
With this partnership, “miSignal™” series, an early stage cancer detection test utilizing urinary miRNA, will be provided as a preferential service for Tokio Marine & Nichido Life Insurance customers
Craif and Nonagen Bioscience to collaborate to evaluate a novel cancer diagnostic test
Craif launches “miSignal™” series which enables early-stage cancer detection using urinary miRNA. The first test from the series will be available from February 2022.
Craif presents study results of urinary biomarker for SLE at ACR Convergenc
Craif Secures Series B Funding
to Accelerate R&D for the Roll-Out of a New Cancer Test